Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
4.5
Journals
Biomedicines
Special Issues
State-of-the-Art Drug Discovery and Development in Poland (3rd Edition)
share announcement

State-of-the-Art Drug Discovery and Development in Poland (3rd Edition)

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Drug Discovery, Development and Delivery".

Deadline for manuscript submissions: 30 November 2026 | Viewed by 1367

Editor

Dr. Aleksandra Romaniuk-Drapała

E-Mail Website
Guest Editor
Department of Clinical Chemistry and Molecular Diagnostics, Poznan University of Medical Sciences, Collegium Pharmaceuticum, 3 Rokietnicka Str., 60-806 Poznan, Poland
Interests: combination chemotherapy, drug delivery; targeted therapy; cancer biology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Over the past few decades, we have observed a significant shift in drug design and development modes. Two distinct technological trends are involved in this change. One explores advances in areas such as genomic sequencing, protein science, and structural biology. New technologies provide vast amounts of data, uncover a wide range of potential drug targets, and facilitate more accurate target identification and validation. The other empowers computational scientists to utilize these massive databases thanks to the significant number of tools and software available for analyzing and interpreting biological complexity. Technological advances in various areas of omics have allowed the exploration of different approaches to improve drug design and development success.

All authors actively involved in drug discovery and development in Poland are invited to contribute to this Special Issue. Original research articles and reviews on the hottest topics related to identifying and introducing new medicines and cutting-edge methodological advances are welcome.

Research topics include but are not limited to:

  • In silico drug target profiling;
  • Drug delivery systems;
  • Drug–drug interaction;
  • Target-based screening;
  • Phenotypic screening;
  • Pharmaceutical modeling;
  • Computational chemistry;
  • Targeted therapy;
  • Biomarkers;
  • Bioimaging.

Dr. Aleksandra Romaniuk-Drapała
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • in silico drug target profiling
  • drug delivery systems
  • drug–drug interaction
  • target-based screening
  • phenotypic screening
  • pharmaceutical modeling
  • computational chemistry
  • targeted therapy
  • biomarkers
  • bioimaging

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

30 pages, 1291 KB  
Review
Nanocarrier-Based Therapeutic Strategies in Myocardial Ischemia–Reperfusion Injury: A Systematic Review of Preclinical Evidence
by Michał Porada, Bartosz Pawełczak, Karolina Barańska-Pawełczak and Krzysztof Marciniec
Biomedicines 2026, 14(4), 921; https://doi.org/10.3390/biomedicines14040921 - 17 Apr 2026
Viewed by 830
Abstract
Background/Objectives: Myocardial ischemia–reperfusion injury (MIRI) remains an ever-growing threat in the field of cardiology, as it has become a major risk factor for unfavorable outcomes following reperfusion therapies. Oxidative stress and inflammation remain the key pathophysiological mechanisms underlying MIRI, and the presently [...] Read more.
Background/Objectives: Myocardial ischemia–reperfusion injury (MIRI) remains an ever-growing threat in the field of cardiology, as it has become a major risk factor for unfavorable outcomes following reperfusion therapies. Oxidative stress and inflammation remain the key pathophysiological mechanisms underlying MIRI, and the presently available treatments fail to prevent this process effectively. This systematic review aimed to summarize and critically assess the latest preclinical research (2020–2026) on nanocarrier-based interventions targeting oxidative stress in MIRI, highlighting the potential of the new nanostructures in cardioprotection. Methods: A total of 24 studies meeting the PRISMA criteria have been found through a literature search of PubMed, Embase, and Web of Science databases published between 2020 and 2026. The studies eligible for inclusion had focused on the efficacy of nanocarrier-based interventions in preclinical studies of MIRI. Results: Of the 24 included studies, all investigated nanocarrier-based interventions in preclinical models of MIRI. In vitro, ex vivo, and in vivo models were diverse, with most studies being a combination of both in vitro and in vivo models. Commonly studied were lipid-based nanocarriers, polymeric nanoparticles, and biomimetic nanocarriers. Across studies assessed for this review, treatments with nanocarriers were seen to suppress inflammatory and oxidative stress pathways, with a few studies showing a suppression of cardiomyocyte apoptosis. Cardiac function was restored as determined by echocardiography analyses or ex vivo models of the myocardium, thus validating that the nanocarrier-mediated therapies are effective against MIRI. Conclusions: The analyzed preclinical studies indicate that the described therapies could provide a promising basis for future clinical trials in the treatment of MIRI, provided their safety and efficacy are confirmed in clinical trials. Full article
(This article belongs to the Special Issue State-of-the-Art Drug Discovery and Development in Poland (3rd Edition))
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop